Technology | March 10, 2008

Bayer HealthCare Opens Door to Tracking Contrast Media

Bayer HealthCare Pharmaceuticals Inc. offers VistaTrak, a contrast media management system that provides a new management tool designed to help enhance patient care and safety, optimize inventory management and improve billing accuracy.

VistaTrak is a collaboration between Bayer HealthCare Pharmaceuticals and Mobile Aspects, a provider of Radio Frequency Identification (RFID)-enabled solutions for healthcare and hospital environments. The companies worked together to optimize Mobile Aspects’ proprietary iRIS platform for clinical environments that use contrast media. Bayer is the first company to offer a contrast media management system based on an RFID platform to automate manual processes and capture valuable operational data that currently cannot be found in any one system.

The system combines RFID technology of “tagged” bottles of contrast agent with a “smart” cabinet and a specially designed interface to capture, store and manage product utilization data easily and reliably while helping to reduce the risk of human error. It provides solutions for the use of contrast media, such as:
• Facilitating patient safety by automatically screening data from a patient’s electronic medical record (EMR) for, among other things, contraindications and prior adverse events
• Capturing information stored on the tag, such as NDC number, expiration date and lot number, automatically and in an efficient manner that supports compliance with accrediting organization requirements
• Providing contrast dosing information to improve billing accuracy and help address any existing issues with reimbursement or audits
• Tracking inventory to enable departments to order and manage inventory more efficiently and reduce waste

VistaTrak features a touch-screen interface and is available in two different sizes to address varying usage needs.

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init